JWH-370

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields =

| verifiedrevid =

| IUPAC_name = [5-(2-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone

| image = JWH-370.svg

| width =

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA = Schedule II

| legal_DE =

| legal_UK = Class B

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct}}

| CAS_number = 914458-22-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = HJZ9JN4HNM

| ATC_prefix =

| ATC_suffix =

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL =

| PubChem = 44418312

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 23277889

| C=27 | H=27 | N=1 | O=1

| smiles = CCCCCN1C=C(C=C1C2=CC=CC=C2C)C(=O)C3=CC=CC4=CC=CC=C43

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C27H27NO/c1-3-4-9-17-28-19-22(18-26(28)23-14-7-5-11-20(23)2)27(29)25-16-10-13-21-12-6-8-15-24(21)25/h5-8,10-16,18-19H,3-4,9,17H2,1-2H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = HZMLAMXVETUEJZ-UHFFFAOYSA-N

}}

JWH-370 ([5-(2-methylphenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 5.6 ± 0.4nM) and CB2 (Ki = 4.0 ± 0.5nM) receptors, with a slight selectivity for the CB2 receptor. JWH-370 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.{{cite journal | vauthors = Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR | title = 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors | journal = Bioorganic & Medicinal Chemistry Letters | volume = 16 | issue = 20 | pages = 5432–5 | date = October 2006 | pmid = 16889960 | doi = 10.1016/j.bmcl.2006.07.051 }}

Legality

In the United States JWH-370 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-370.{{UnitedStatesCode2|21|812|Schedules of controlled substances}}{{cite web |title=The 2020 Florida Statutes |url=http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html |website=www.leg.state.fl.us |access-date=20 August 2021}}{{cite web |title=Arizona Revised Statutes Title 13. Criminal Code § 13-3401 |url=https://www.azleg.gov/ars/13/03401.htm |website=www.azleg.gov |access-date=20 August 2021}}{{cite web |title=California Code, Health and Safety Code - HSC § 11357.5 |url=https://codes.findlaw.com/ca/health-and-safety-code/hsc-sect-11357-5.html |website=Findlaw}}

In Canada, JWH-370 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.{{cn|date=August 2021}}

In the United Kingdom, JWH-370 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.{{cn|date=August 2021}}

See also

References